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1494Objectives: Chronic right ventricular (RV) pressure overload results in pathologic RV hypertrophy and dimin-
ished RV function. Although aortic constriction has been shown to improve systolic function in acute RV failure,
its effect on RV responses to chronic pressure overload is unknown.
Methods:Adjustable vascular banding devices were placed on the main pulmonary artery and descending aorta.
In 5 animals (sham group), neither band was inflated. In 9 animals (PAB group), only the pulmonary arterial
band was inflated, with adjustments on a weekly basis to generate systemic or suprasystemic RV pressure at
28 days. In 9 animals, both pulmonary arterial and aortic devices were inflated (PABþAO group), the pulmonary
arterial band as for the PAB group and the aortic band adjusted to increase proximal systolic blood pressure by
approximately 20 mm Hg. Effects on the functional performance were assessed 5 weeks after surgery by con-
ductance catheters, followed by histologic and molecular assessment.
Results: Contractile performance was significantly improved in the PABþAO group versus the PAB group for
both ventricles. Relative to sham-operated animals, both banding groups showed significant differences in myo-
cardial histologic and molecular responses. Relative to the PAB group, the PABþAO group showed significantly
decreased RV cardiomyocyte diameter, decreased RV collagen content, and reduced RVexpression of endothe-
lin receptor type B, matrix metalloproteinase 9, and transforming growth factor b genes.
Conclusions:Aortic constriction in an experimental model of chronic RV pressure overload not only resulted in
improved biventricular systolic function but also improved myocardial remodeling. These data suggest that
chronically increased left ventricular afterload leads to a more physiologically hypertrophic response in the
pressure-overloaded RV. (J Thorac Cardiovasc Surg 2012;144:1494-501)The right ventricle (RV) may be subjected to an abnormally
high afterload in patients with various types of congenital
and acquired heart disease and also in idiopathic, hereditary
or other forms of pulmonary arterial (PA) hypertension.1
The RV typically shows progressive remodeling, including
increased wall thickness, myocardial hypertrophy, and in-
terstitial fibrosis. This initially adaptive compensatory hy-
pertrophy eventually becomes maladaptive and may
eventually progress to RV dilatation and failure,2,3 the
development of which is a universally poor prognostic
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The Journal of Thoracic and Cardiovascular Surare usually associated with marked changes in myocardial
fibrotic signaling. Among others increased levels of endo-
thelin 1 (ET-1), matrix metalloproteinase (MMP) 9, and
transforming growth factor b (TGF-b) have been observed
as markers of maladaptive hypertrophy and fibrosis in
models of left ventricular (LV) dysfunction and failure
and may also play a role in RV failure.5
The pathophysiology of RV failure, particularly with re-
gard to adverse ventricular-ventricular interactions, is be-
coming increasingly understood. For example, in a study
of patients with chronic idiopathic pulmonary hyperten-
sion, right heart dilation altered LV geometry and diastolic
function, as assessed by Doppler echocardiography, and
was associated with worse outcomes.6 Furthermore, in
a magnetic resonance study, Gan and coworkers7 demon-
strated that cardiac output was inversely related to LV
end-diastolic dimension (because it is compressed by the
RV), rather than to RV function per se.7 Conversely, it
may therefore be possible that modification of these ad-
verse ventricular-ventricular interactions may lead to
some benefits. It is well known that superficial myocardial
fibers are shared and continuous between the RV and the
LV, providing an anatomic basis for normal and abnormal
ventricular-ventricular interactions.8 Indeed, in an elegantgery c December 2012
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Sstudy of normal hearts, in which the ventricles were elec-
trically isolated but mechanically intact, Damiano and col-
leagues9 showed that under basal conditions LV
contraction contributed more than 65% of the work of
the normal RV. These normal interactions form the basis
of beneficial interventions in models of acute RV failure.
Yamashita and coworkers10 showed that increased LV
afterload, produced by aortic constriction, both restored
LV dimensions and improved RV stroke volume in the set-
ting of acute pulmonary embolic shock. Similarly, Be-
lenkie and coworkers11 showed a beneficial effect of
aortic constriction (independent of changes in coronary
flow) in experimental RV failure induced by acute banding
of the PA,11 and our own recent data in a similar PA-
banding model showed that improvement in RV contractil-
ity assessed by conductance catheter could be induced
both by acute aortic banding and by pharmacologically in-
creasing LV afterload with norepinephrine.12 We specu-
lated that the improved RV contractility was manifested
through harnessing of the Anrep effect of increased LV
afterload, leading to increased LV contractility, which in
turn was transmitted to the RV through the crosstalk
mechanism shown by Damiano and colleagues,9 but
clearly other factors, such as changes in septal position,
may also contribute to this phenomenon.
To date, there have been no studies of the effect of in-
creased LVafterload on RV responses in chronic RV failure.
The purpose of this study was therefore to investigate the ef-
fect of chronic aortic constriction on biventricular structuralThe Journal of Thoracic and Carand functional responses in an experimental model of
chronic RV pressure overload. We hypothesized that aortic
constriction would improve RV function and myocardial re-
modeling in this setting.MATERIALS AND METHODS
All authors had full access to and take full responsibility for the integrity
of the data. All authors have read and agree to the article as written. All ex-
periments were approved by the animal ethics committee of the Hospital
for Sick Children, Toronto, Ontario, Canada, and were done in accordance
with the ‘‘Guiding Principles in the Care and Use of Animals’’ of the Amer-
ican Physiologic Society.
Preparation
Twenty-three adult New Zealandwhite rabbits were studied. After intra-
venous cannulation (24G Angiocath; BD, Franklin Lakes, NJ) of the ear
marginal vein, anesthesia was initiated by the use of isoflurane (3%) and
acepromazine maleate (INN acepromazine, 1.1 mg/kg). After tracheal in-
tubation, ventilation was controlledmechanically tomaintain normal blood
gas values (PaCO2 of 32-35 mm Hg). General anesthesia was maintained
with isoflurane (1.5%-2%). Heart rate and oxygen saturation were contin-
uously monitored.
Banding Devices
For incremental banding of the pulmonary trunk and ascending aorta,
we used a recently developed adjustable banding device (ABS; Silimed
Inc, Rio de Janeiro, Brazil).13 The band consists of a banding ring, a con-
necting tube, and an inflation reservoir. The banding ring is a C-shaped hy-
draulic cuff with a 5 mm width and a rigid outer layer, reinforced with
a polyester mesh, which keeps it from deforming centrifugally. The cuff
compresses the lumen of the vessel when expanded in proportion to the vol-
ume injected into the inflation reservoir. The connecting tube hermetically
connects the banding ring to the inflation reservoir, which is covered by
a silicone membrane to allow repeated percutaneous needle puncture for
adjustment of the degree of vascular constriction. In all animals, adjustable
banding devices were placed on the pulmonary trunk and descending aorta
through a left lateral thoracotomy, then the connecting tubes were tunneled
toward each of the inflation reservoirs, which were placed subcutaneously
in the neck.
After band placement, the animals were then allocated to either the PAB
group, which underwent PA band inflation alone (n ¼ 9); the PABþAO
group, which underwent both PA and aortic band inflation (n ¼ 9); or the
sham group, which did not have the devices inflated (n ¼ 5).
After a recovery period of 7 days, each animal in the PAB and PABþAO
groups received stepwise percutaneous inflation of the cuff around the PA
to induce RV pressure overload. Doppler echocardiography was used to
monitor RV pressure (estimated by Doppler assessment of the tricuspid re-
gurgitation) and the RV/PA pressure gradient (estimated byDoppler assess-
ment of gradient across the PA band). Three incremental PA band
adjustments were performed on a weekly basis. Initially, the banding was
calibrated to an RV pressure of approximately half systemic pressure, at
second banding to between two thirds and three quarters of systemic pres-
sure, and to systemic levels on the 3rd occasion. In the PABþAO group, the
aortic banding was also adjusted at each stage to maintain a gradient of ap-
proximately 20 mm Hg across the band (as measured by Doppler
echocardiography).
Functional Assessment
Hemodynamic measurements were performed in all animals 5 weeks af-
ter pulmonary banding-operation (after 2 weeks of systemic RV pressure).
A 3F conductance catheter (Millar Instruments, Inc, Houston, Tex) was ad-
vanced to each ventricle for simultaneous measurement of pressures anddiovascular Surgery c Volume 144, Number 6 1495
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Svolumes through a neck vein and a neck artery, respectively. For preload
reduction, required to obtain pressure-volume relationships, a balloon cath-
eter (10-mm Tyshak balloon; NuMED Canada Inc, Cornwall, Ontario,
Canada) was introduced through a groin vein and was placed in the inferior
caval vein under fluoroscopic guidance. For all conditions, steady-state he-
modynamic data were recorded during short periods of suspended ventila-
tion at end-expiration. Indices of systolic and diastolic function were
derived from pressure-volume loops recorded during inflation of a balloon
catheter in the inferior caval vein to reduce RV preload. For systolic ven-
tricular function, we determined end-systolic elastance as the slope of
the end-systolic pressure-volume relationship (ESPVR) and preload re-
cruitable strokework (PRSW) from a family of pressure-volume loops dur-
ing progressive occlusion of the inferior caval vein. Diastolic stiffness was
determined as the slope of the end-diastolic pressure-volume relationship
(EDPVR).
Tissue Collection
Each animal was killed after hemodynamic measurements were made.
The LVand RV samples were cut into 2 parts, 1 of which was immediately
snap-frozen in liquid nitrogen and stored at80C for RNA and protein
analysis. The other part was fixed in 10% neutral-buffered formaldehyde
and embedded in paraffin. The 5-mm cross-sections of RV and LV were
cut and stained with hematoxylin-eosin, picrosirius red (PSR) F3BA, and
Masson trichrome (MT) stains.
Histologic Analysis
Interstitial collagen in transverse cardiac section was evaluated by PSR
andMT staining. Interstitial collagen was identified in the PSR-stained sec-
tions by its red appearance and in the MT-stained sections by its blue ap-
pearance. The cardiac interstitial collagen content was measured and
expressed as a percentage of the total collagenous and noncollagenous
areas in the entire visual field of the section by automated planimetry
with Adobe Photoshop CS2 software (Adobe Systems Inc, San Jose, Calif).
The myocyte diameter was measured with images captured from hematox-
ylin-eosin–stained sections. A point-to-point perpendicular line was placed
across the longitudinally cut myocyte at the level of the nucleus, and this
diameter length was then measured by the National Institutes of Health Im-
ageJ analysis program (http://rsbweb.nih.gov/ij/). All the longitudinally di-
rected myocytes with a distinct cell border (at the level of the nucleus)
within the sampling field were measured and averaged to provide the
mean cardiomyocyte diameter. Transverse or obliquely cut myocytes
were excluded. Cell width was determined from longitudinally positioned
myocytes to reduce the error of determining such for myocytes that might
not have been cut precisely perpendicular to their long axis.TABLE 1. Hemodynamic and functional data
Sham PAB
RV Pes (mm Hg) 14.4  1.2 52.6  3.1
RV Ped (mm Hg) 1.6  0.4 2.1  0.4
RV PRSW (mm Hg) 1.5  1.3 4.1  0.9
RV ESPVR (mm Hg/mL) 2.7  0.3 7.7  2.9
RV EDPVR (mm Hg/mL) 0.8  0.3 1.3  0.5
LV Pes (mm Hg) 36.1  2.2 48.0  0.9
LV Ped (mm Hg) 1.2  0.5 1.5  0.5
LV PRSW (mm Hg) 13.3  5.7 13.4  1.2
LV ESPVR (mm Hg/mL) 10.6  0.9 11.3  2.5
LV EDPVR (mm Hg/mL) 1.1  0.1 1.3  0.3
All values are mean  SEM. EDPVR, End-diastolic pressure-volume relationship; ESPV
(P>.05); PAB, pulmonary arterial banding alone [group]; PABþAO, pulmonary arterial
PRSW, preload recruitable stroke work; RV, right ventricular. *Sham versus pulmonary ar
zPulmonary arterial banding alone versus pulmonary arterial banding plus aortic banding
1496 The Journal of Thoracic and Cardiovascular SurReal-Time Reverse Transcriptase–Polymerase Chain
Reaction Analysis
Total RNAwas extracted from RVand LV tissues with TRIzol Reagent
(Invitrogen Corp, Grand Island, NY). Reverse transcription proceeded
with 1 mg of total RNAwith SuperScript III First-Strand Synthesis System
(Invitrogen). Real-time polymerase chain reaction was carried out with
SYBR Green Master Mix (Applied Biosystems, Life Technologies Corpo-
ration, Carlsbad, Calif). Glyceraldehyde 3-phosphate dehydrogenase gene
(GAPDH) was used as the endogenous reference. Primers are listed as fol-
lows: ET-1 gene (EDN1), forward 50-ACTTCTGCCACCTGGACATCA-30,
reverse 50-ACGCTGCCCTGGTAGGAAAT-30; endothelin receptor type A
gene (EDNRA), forward 50-GCTTCTTGCTGCTCATGGATTAC-30, re-
verse 50- CCGAGGTCATCAGGCTCTTG-30; endothelin receptor type B
gene (EDNRB), forward 50-CTGGCCATTTGGAGCTGAGA-30, reverse
50-TTTGGAACCCCAATTCCTTTAA-30; MMP-2 gene (MMP2), forward
50- AGGACTACGACCGCGACAAG-30, reverse 50- TGTTGCCCAG
GAAGGTGAAG -30; MMP-9 gene (MMP9), forward 50-CTTCCAACTTT
GACAGCGACA-30, reverse 50-GGAGTGATCCAAGCCCAGTG-30;
TGF-b gene (TGFB), forward 50-AGGGCTACCACGCCAACTT-30, re-
verse: 50-CCGGGTTGTGCTGGTTGTAC-30, connective tissue growth
factor gene (CTGF), forward 50-CCCTGCGTCTTCGGTGGC-30, reverse
50-AGGCAGTTGGCTCGCATCAT-30; and GAPDH, reverse 50-AGG
CCGTGGGCAAGGT-30, reverse 50-CCTCGGATGCCTGCTTCA-30.
Statistical Analysis
Data are expressed as mean  SEM. Results were analyzed by analysis
of variance for repeated measurements. GraphPad software (GraphPad
Software Inc, San Diego, Calif) was used for statistical analysis.RESULTS
Hemodynamic and Functional Characteristics
During the postsurgical periods, all animals gained weight
and showed no clinical signs of heart failure. Water and food
were available ad libitum, and intakewas normal. Populations
were similar in each group in terms of age and bodyweight at
time of the initial and terminal experiments. Hemodynamic
and functional data are listed in Table 1. As expected, PA
banding resulted in a significant increase in RV systolic pres-
sure relative to the shamgroup (P<.01) andwas not different
between the PAB and PABþAO groups. The slopes of RV
ESPVR and RV PRSW were also significantly increased inP
value* PABþAO
P
valuey
P
valuez
<.01 52.7  2.3 <.01 NS
NS 4.0  0.7 <.01 <.05
<.05 13.6  5.1 <.0001 <.05
<.05 13.9  4.9 <.0001 <.05
NS 2.2  0.5 NS NS
NS 74.3  3.9 <.01 <.05
NS 4.9  0.6 <.01 <.01
NS 22.6  4.6 <.05 <.05
NS 18.2  1.5 <.05 <.05
NS 2.4  0.4 <.05 <.05
R, end-systolic pressure-volume relationship; LV, left ventricular; NS, not significant
and aortic banding [group]; Pes, end-systolic pressure; Ped, end-diastolic pressure;
terial banding alone. ySham versus pulmonary arterial banding plus aortic banding.
.
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FIGURE 1. Hematoxylin-eosin staining showed a significantly increased cardiomyocyte diameter in the pulmonary arterial banding only (PAB) group for
the right ventricle (RV) and for the left ventricle (LV). Addition of aortic banding (PABþAO) resulted in a significantly decreased cardiomyocyte diameter for
both ventricles. Asterisk indicates P<.05.
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sure in the RV tended to increase in the PAB group relative to
the sham group, but not significantly. In the LV, end-systolic
pressure, end-diastolic pressure, and the slopes of LVESPVR
and LV PRSW did not differ significantly between the PAB
group and the sham group.
Additional aortic banding (PABþAO) resulted in further
functional improvement. Relative to the PAB group,
ESPVR and PRSW were significantly higher in the
PABþAO group for the RV (RV ESPVR, 13.9 vs 7.7 mm
Hg/mL; P<.05; RV PRSW, 13.6 vs 4.1; P<.05) and for
the LV (LV ESPVR 18.2 vs 11.3 mm Hg/mL; P<.05; LV
PRSW, 22.6 vs 13.4; P<.05), reflecting improved biven-
tricular contractility.
Diastolic RV stiffness, as assessed by RV EDPVR, was
not different in either intervention group relative to the
sham group, whereas the end-diastolic RV pressure was sig-
nificantly increased in the PABþAO group relative to the
PAB and sham groups. In the LV, there were significant in-
creases in both LV EDPVR and end-diastolic LV pressure in
the PABþAO group relative to the PAB and sham groups.Histologic Remodeling
Hematoxylin-eosin staining showed significantly in-
creased cardiomyocyte diameters in the PAB group relative
to the sham group (22.88 0.87 mm vs 16.03 0.47 mm for
the RV and 21.53  0.54 mm vs 16.12  0.41mm for the
LV; Figure 1). Additional aortic banding resulted inThe Journal of Thoracic and Carsignificantly decreased cardiomyocyte diameters in the
PABþAO group (18.8  0.99 mm for the RV and 18.47 
1.01 mm for the LV) relative to the PAB group.
Both PSR and MT staining revealed significant increases
in collagen in both the RV (PSR staining, 10.78% 1.39%
vs 3.74% 0.34%; MT staining, 9.2% 1.73% vs 2.12%
 0.31%) and the LV (PSR staining, 5.28%  0.48% vs
2.86%  0.3%; MT staining, 2.5%  0.46% vs 0.9% 
0.23%) for the PAB group relative to the sham group
(P<.05). Addition of aortic banding resulted in significant
decreases in collagen in both the RV (PSR staining, 6.61%
 0.85%; MT staining, 4.78% 0.77%) and the LV (PSR
staining, 3.81%  0.36%; MT staining, 1.8%  0.33%)
for the PABþAO group (P<.05) (Figure 2).Molecular Assessment
Expression of EDN1 was significantly increased in the
RV myocardium in both the PAB group (2.22  0.42) and
the PABþAO group (2.18  0.28) relative to the sham
group (1.07  0.19; P<.05; Figure 3, A). Interestingly, ex-
pression of EDN1was also significantly increased in the LV
myocardium in both the PAB group (2.5  0.26) and the
PABþAO group (2.99  0.19) relative to the sham group
(1.14  0.26; P<.05; Figure 4, A). RV and LV myocardial
expressions of EDNRAwere not different in either interven-
tion group relative to the sham group (RV, 1.16  0.11 and
1.06 0.07 vs 1.02 0.11, respectively; P not significant),
(LV, 1.1  0.06 and 0.89  0.07 vs 1.02  0.11,diovascular Surgery c Volume 144, Number 6 1497
FIGURE 2. Representative sections showing Masson trichrome (MT) staining for collagen content. The bar graph of the quantitative analysis shows
increased collagen in response to pulmonary arterial banding (PAB) in both the right ventricle (RV) and the left ventricle (LV). Addition of aortic banding
(PABþAO) significantly attenuated this increase in the right ventricle but not in the left ventricle. Asterisk indicates P<.05.
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trast was significantly elevated in the RV in the PAB group
(1.95 0.3) relative to the sham group (1.02 0.1; P<.05)
but not in the PABþAO group (1.52 0.3; P not significant;
Figure 3, A). There were no differences among the groups in
EDNRB expression in the LV (Figure 4, A).
MMP9 expressions were significantly elevated in the RV
myocardium in both the PAB group (2.12  0.32) and the
PABþAO group (1.38  0.12) relative to the sham group
(0.88  0.2; P < .05), whereas in the LV myocardium
MMP9 expressions were not different in either the PAB
group (2.32  0.39) or the PABþAO group (1.83  0.18)
relative to the sham group (1.21  0.43; P not significant).
MMP2 expressions were not elevated (1.07 0.16 and 0.96
 0.13 vs 1.01  0.16) in either ventricle. In the RV myo-
cardium, TGF-b expression was significantly increased in
the PAB group (1.4  0.13) relative to the sham group
(0.84  0.16; P< .05; Figure 3, B) and was significantly
lower in the PABþAO-group (0.93  0.1) relative to the
PAB group (P<.05). A similar pattern of TGF-b expression
was seen in the LV (Figure 4, B). There were no statistically
significant differences in CTGF expressions between any of
the groups in either ventricle.
DISCUSSION
This study demonstrates that chronic aortic constriction
not only improves RV function but also leads to less malad-
aptive RV remodeling in response to chronic RV pressure
overload.1498 The Journal of Thoracic and Cardiovascular SurProgressive RV remodeling, including increased wall
thickness and myocardial hypertrophy, as well as interstitial
fibrosis, is a hallmark of PA hypertension.14 This initially
adaptive hypertrophy eventually becomes maladaptive,
and RV failure ensues. Clinically manifest RV failure is con-
sistently reported as an adverse risk factor for survival in pa-
tients with pulmonary hypertension,4 and although its onset
may be delayed by the use of advanced pulmonary vasodila-
tor therapies, such as prostanoids, phosphodiesterase type 5
inhibitors, and endothelin receptor blockers, in the absence
of a curative therapy it is likely that progression toRV failure
and death will be the final common pathway for these pa-
tients. Although not ignoring the huge impact of vasodilator
therapies, the potential for modifying RV function as
a method of improving symptoms and survival has been
emphasized in several recent reviews.15-17 Whereas these
reviews have speculated that specific therapies may be
developed to target the RV itself, there is evidence from
both experimental and clinical studies that symptoms and
outcomes may be driven by adverse ventricular-ventricular
interactions related to the dilated and poorly functioning
RV modifying the systolic and diastolic performance of
the LV.We believe that the heart failure associated with pro-
gressive pulmonary hypertension should be considered a bi-
ventricular disease and that therapies targeted toward both
ventriclesmay therefore be beneficial. Indeed,we and others
have shown that other ventricular-ventricular interactions
can be harnessed for potential therapeutic benefit, at least
acutely, in the setting of pulmonary hypertension.11,12 Forgery c December 2012
FIGURE 3. Results of real-time polymerase chain reaction analysis of
right ventricular (RV) myocardium. A, Expressions of endothelin 1 gene
(EDN1) and endothelin receptor B gene (EDNRB) expressions were signif-
icantly increased in the pulmonary arterial banding (PAB) group and in the
group with added aortic banding (PABþAO) relative to the sham group,
while there was no effect on endothelin receptor A gene (EDNRA) expres-
sion. B, Messenger RNA (mRNA) levels for genes for matrix metalloprotei-
nases 2 (MMP2) and 9 (MMP9), transforming growth factor-b (TGF b) and
connective tissue growth factor (CTGF). Expressions of matrix metallopro-
teinase 9 and transforming growth factor b genes were significantly in-
creased in the pulmonary arterial banding group relative to the sham
group. Addition of aortic banding was associated with significantly re-
duced transforming growth factor b gene expression and a trend toward re-
duced matrix metalloproteinase 9 gene expression. There was no
statistically significant change in connective tissue growth factor gene ex-
pression. Asterisk indicates P<.05.
FIGURE 4. Results of real-time polymerase chain reaction analysis of left
ventricular (LV) myocardium. A, Expression of endothelin 1 gene (EDN1)
was significantly increased in left ventricular myocardium in the pulmo-
nary arterial banding (PAB) group and in the group with added aortic band-
ing (PABþAO) relative to the sham group, while there was no effect on
endothelin receptor A gene (EDNRA) and endothelin receptor B gene
(EDNRB) expressions. B,Messenger RNA (mRNA) levels for genes for ma-
trixmetalloproteinases 2 (MMP2) and 9 (MMP9), transforming growth fac-
tor b (TGF b), and connective tissue growth factor (CTGF). Transforming
growth factor b genewas significantly increased in the left ventricular myo-
cardium in the pulmonary arterial banding group relative to the sham
group. Addition of aortic banding was associated with significantly re-
duced transforming growth factor b gene expression. There was no statis-
tically significant change in matrix metalloproteinase 2, matrix
metalloproteinase 9, and connective tissue growth factor gene expressions
in the left ventricular myocardium. Asterisk indicates P<.05.
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effect (increased LV contractility in response to increased
LV afterload by aortic constriction or pharmacologic
systemic arterial vasoconstriction) leads to improved
RV contractility in models of acute RV failure. To date,
there have been no studies of this potential effect on
biventricular responses to a chronically increased RV
afterload, despite the potential therapeutic benefits that
this novel approach may offer.
In the chronic PAbandingmodel used in this study, RV re-
modeling was characterized by increases in both RV mass
and cardiomyocyte diameter. In addition, there was exces-
sive interstitial myocardial fibrosis, as evidenced by in-
creased collagen content, characteristic of the failing RV
myocardium.14 Concomitant aortic banding not only par-
tially abrogated these histologic changes but also wasThe Journal of Thoracic and Carassociated with significantly improved RV function. Indeed,
both the RVand the LV showed significantly improved sys-
tolic function, as measured by relatively load-independent
indices derived from conductance catheter measurements.
It is important to note that these improvements occurred in
the presence of maladaptive RV remodeling (RV hypertro-
phy, increased cardiomyocyte diameter, and fibrosis) but be-
fore the development of overt RV failure (preserved RV
ESPVR). When extrapolating to potential clinical applica-
tions, this seems to be the window when intervention would
be most timely—when signs of RV remodeling are present,
but before overt and irreversible RV failure has occurred.
The maladaptive hypertrophy seen in the PAB group was
associatedwithmarked changes inmyocardial fibrotic signal-
ing. The profile of increased EDN1, MMP9, and TGF-b ex-
pressions observed in the PAB group is consistent with thediovascular Surgery c Volume 144, Number 6 1499
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LV dysfunction and failure, and each presents potential ther-
apeutic targets identified in a recent comprehensive review.5
Our data are consistent with those shown for the pressure-
loaded LV, and the effect of aortic banding is consistent
with it being an intervention that alters themaladaptive signa-
ture, toward amore physiologic response. Concomitant aortic
banding led to a decrease in histologic fibrosis and was asso-
ciated with reduced TGF-b, CTGF, andMMP9 expressions.
Although the signaling pathways that relate to these mol-
ecules have been studied extensively in the LV, less is
known about their interrelationship in the RV subjected to
chronic pressure load. TGF-b regulates growth, differentia-
tion, and function of different cell lineages (eg, myocytes,
endothelial cells, and fibroblasts) and has recently been im-
plicated in maladaptive RV failure associated with pulmo-
nary hypertension.18 Furthermore, RV myocardial fibrosis,
TGF-b signaling, and degradation of the matrix by MMPs
have shown to be linked in earlier studies of chronic pres-
sure overload and to adversely affect myocardial systolic
and diastolic function.19,20 In the LV, TGF-b signaling
regulates EDN1 expression via the JNK pathway, the
effect of which in turn is regulated downstream by CTGF.
Interestingly, the pattern of change in CTGF expression in
our groups (a rise in the PAB group, which was attenuated
in the PABþAO group) was similar to those of TGF-
b and MMP9, although the magnitude of difference did
not reach statistical significance. We did, however,
observe significantly increased myocardial expression of
EDN1 in both the PAB and the PABþAO groups.
Previous clinical studies of pulmonary hypertension have
suggested that high circulating ET-1 levels are caused by
increased gene expression and consequent synthesis, with-
out a loss of the ET-1 clearance activity that normally oc-
curs.21-23 Whether our findings would be reflected by
increased circulating levels of ET-1 or are limited to myo-
cardial expression remains to be demonstrated, but it ap-
pears that the profibrotic responses to increased EDN1
expression (which was similarly elevated in both PAB and
PABþAO groups, despite demonstrable differences in fi-
brosis by histologic examination) were in some way atten-
uated, presumably through regulation of upstream effects
of reduced TGF-b or downstream through reduced receptor
stimulation. With regard to the latter, our findings of de-
creased EDNRB expression may be important.
It was beyond the scope of this proof-of-principle study to
explore fully the potential mechanisms bywhich aortic band-
ing modifies the functional or molecular responses in the RV
subjected to chronically increased afterload. A limitation of
the study is thatwe are unable to comment on themechanisms
of adaptationwith regard to thepositionof theventricular sep-
tum. We speculate, however, that improved functional re-
sponses of the RV via the beneficial ventricular-ventricular
interaction from increased LV afterload and increased1500 The Journal of Thoracic and Cardiovascular Surcontractility beneficially modifies the hemodynamic and
myocardialmilieu to reduce heart failure responses.Our find-
ing of reducedMMP-9 signaling would be consistent with at-
tenuation of myocardial oxidative stress,24 itself a potent
stimulator of adverse remodeling. In turn, adverse proinflam-
matory and profibrotic responses are attenuated, leading to
more physiologic hypertrophy of the myocardium.
Thepotential therapeutic implications of ourfindingsmust
also remain similarly speculative. Systemic vasoconstrictor
therapy to recapitulate the effects of aortic constriction in pa-
tients would be neither easy to perform nor readily adopted
by clinicians and patients. Our observations regarding the
profibrotic responses within the RV do raise the possibility
of using other agents to modify RV responses. Endothelin
blockade is already widely used for patients with advanced
pulmonary hypertension, but it might be argued that it would
need to be given earlier in the course of the disease if it were
to have a beneficial effect on RV remodeling. In this regard,
modification of TGF-b signaling might be a more attractive
target. It may be possible to modify fibrotic responses asso-
ciated with increased TGF-b signaling through angiotensin
II with an angiotensin receptor blocker, in the same way as
has been shown in models of LV disease.25
In summary, we have shown that the functional and mo-
lecular maladaptive responses to increased RVafterload are
attenuated by concomitant aortic constriction, presumably
through beneficial ventricular-ventricular interactions. The
molecular responses suggest modification of profibrotic
pathways, which in themselves may be therapeutic targets
to improve RV remodeling in chronic pulmonary hyperten-
sion and other conditions of RV pressure afterload.
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SA casual reader might be tempted to skip over the article
by Apitz and colleagues in this issue, dismissing it as irrel-
evant to clinical practice. The title is also somewhat off-
putting because ‘‘aortic constriction’’ evokes only bad
images in the mind of any cardiac surgeon. In fact, how-
ever, this elegant yet traditional cardiac physiology exper-
iment shows that chronic aortic constriction not only
improves right ventricular (RV) function in the setting of
chronic RV pressure overload but also leads to less malad-
aptive RV remodeling. This article does inform on highly
relevant themes, such as ventricle-ventricle interaction,
timing of RV remodeling, and the molecular signature ofRV profibrotic reactions. It may also open the door to
a very untraditional way of managing the remodeled RV.
The problem of the hypertrophied yet not decompensated
RV is typically solved by an early repair of the anatomy,
such as early repair of tetralogy of Fallot for example.
No one would consider ‘‘banding’’ the aorta to allow for
reverse RV remodeling. What, however, about the thick, fi-
brotic RV in an older patient with unrepaired pulmonary
stenosis? Should we consider, akin to pulmonary artery
banding and left ventricular training in an older patient
with transposition of the great arteries, a period of aortic
afterload increase to reposition the septum and maybe re-
verse some of the myocardial profibrotic signaling? What
about managing the failing postoperative RV? In the set-
ting of good left ventricular function, and in the absence
of any current drugs that can directly increase RV contrac-
tility, systemic afterload increase by pharmacologic means
may in fact have a role to play.
At a time when therapeutic answers are being sought
mostly in genetics and tissue engineering, this study re-
minds us that physiologic research remains an essential
and vital tool.diovascular Surgery c Volume 144, Number 6 1501
